(Q33289791)

English

Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 July 2017

0 references

1 reference

Europe PubMed Central

Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison (English)

1 reference

Europe PubMed Central

25 July 2017

0 references

author name string

H Miles Prince

1

1 reference

Europe PubMed Central

25 July 2017

Michael Adena

2

1 reference

Europe PubMed Central

25 July 2017

Dell Kingsford Smith

3

1 reference

Europe PubMed Central

25 July 2017

Judy Hertel

4

1 reference

Europe PubMed Central

25 July 2017

publication date

28 June 2007

1 reference

Europe PubMed Central

25 July 2017

European Journal of Haematology

1 reference

Europe PubMed Central

25 July 2017

79

1 reference

Europe PubMed Central

25 July 2017

93-99

1 reference

Europe PubMed Central

25 July 2017

2

1 reference

Europe PubMed Central

25 July 2017

International uniform response criteria for multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974816

21 June 2018

A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974816

21 June 2018

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974816

21 June 2018

Thalidomide-induced severe neutropenia during treatment of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974816

21 June 2018

Advances in the treatment of multiple myeloma: the role of thalidomide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974816

21 June 2018

Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974816

21 June 2018

Proteasome inhibition in cancer: development of PS-341.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974816

21 June 2018

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974816

21 June 2018

Long-term outcome of splenectomy for idiopathic thrombocytopenic purpura.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974816

21 June 2018

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974816

21 June 2018

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974816

21 June 2018

Meta-analysis in clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974816

21 June 2018

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00886.X

21 January 2018

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00886.X

21 January 2018

Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00886.X

21 January 2018

Bortezomib in combination with dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00886.X

21 January 2018

Thalidomide and dexamethasone combination for refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00886.X

21 January 2018

Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00886.X

21 January 2018

Thalidomide and dexamethasone for resistant multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00886.X

21 January 2018

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00886.X

21 January 2018

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00886.X

21 January 2018

Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00886.X

21 January 2018

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00886.X

21 January 2018

Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00886.X

21 January 2018

An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00886.X

21 January 2018

Early response predicts thalidomide efficiency in patients with advanced multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00886.X

21 January 2018

Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00886.X

21 January 2018

Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974816

31 October 2018

Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974816

31 October 2018

Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974816

31 October 2018

Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974816

31 October 2018

Thalidomide treatment of resistant or relapsed multiple myeloma patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974816

31 October 2018

Perspective on the current use of bortezomib in multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17608711

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17608711

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/J.1600-0609.2007.00886.X

1 reference

Europe PubMed Central

25 July 2017

1 reference

Europe PubMed Central

25 July 2017

1 reference

Europe PubMed Central

25 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33289791&oldid=1980410456"